Research progress of peroxisome proliferator-activated receptor gamma in inflammatory-related diseases

doi:10.3969/j.issn.1673-8640.2017.02.019

Abstract

Abstract:

Peroxisome proliferator-activated receptor gamma（PPARγ）is a member of type Ⅱ nuclear receptor superfamily,as a ligand-dependent transcription factor. In recent years,studies have shown that activated PPARγ is capable of modulating the expression of numerous genes and is involved in many physiological and pathological processes,including anti-obesity,anti-atherosclerosis,anti-diabetes mellitus,anti-cancer and anti-inflammatory skin diseases. These diseases are closely related to inflammation. In this review,the research progress of PPARγ in inflammation and inflammatory-related diseases will be summarized.

Key words: Peroxisome proliferator-activated receptor gamma, Inflammation, Ligand

CLC Number:

R446.62

REN Runjian, ZHAO Hu, BI Bo. Research progress of peroxisome proliferator-activated receptor gamma in inflammatory-related diseases[J]. Laboratory Medicine, 2017, 32(2): 153-157.

References 31

[1]	.JANANI C,RANJITHA KUMARI B D. PPAR gamma gene-A review[J]. Diabetes Metab Syndr,2015,9(1):46-50.
[2]	.SUGAWARA A,URUNO A,KUDO M,et al.PPARγ agonist beyond glucose lowering effect[J]. Korean J Intern Med,2011,26(1):19-24.
[3]	.TAKADA I, MAKISHIMA M.PPARγ ligands and their therapeutic applications:a patent review (2008-2014)[J]. Expert Opin Ther Pat,2015,25(2):175-191.
[4]	.ZOETE V,GROSDIDIER A,MICHIELIN O.Peroxisome proliferator-activated receptor structures:ligand specificity,molecular switch and interactions with regulators[J]. Biochim Biophys Acta,2007,1771(8):915-925.
[5]	.HALLENBORG P,PETERSEN R K,KOUSKOUMVEKAKI I,et al.The elusive endogenous adipogenic PPARγ agonists:lining up the suspects[J]. Prog Lipid Res,2016,61:149-162.
[6]	.AHMADIAN M,SUH J M,HAH N,et al.PPARγ signaling and metabolism:the good,the bad and the future[J]. Nat Med,2013,19(5):557-566.
[7]	.KIM J H,SONG J,PARK K W.The multifaceted factor peroxisome proliferator-activated receptor γ(PPARγ) in metabolism,immunity,and cancer[J]. Arch Pharm Res,2015,38(3):302-312.
[8]	.BRIGANTI S,FLORI E,BELLEI B,et al.Modulation of PPARγ provides new insights in a stress induced premature senescence model[J]. PLoS One,2014,9(8):e104045.
[9]	.ULRICH-LAI Y M,RYAN K K. PPARγ and stress:implications for aging[J]. Exp Gerontol,2013,48(7):671-676.
[10]	.CROASDELL A,DUFFNEY P F,KIM N,et al.PPARγ and the innate immune system mediate the resolution of inflammation[J]. PPAR Res,2015,2015:549691.
[11]	.KIM J K,MUN S,KIM M S,et al.5,7-Dimethoxyflavone,an activator of PPARα/γ,inhibits UVB-induced MMP expression in human skin fibroblast cells[J]. Exp Dermatol,2012,21(3):211-216.
[12]	.BRIGANTI S,FLORI E,MASTROFRANCESCO A,et al.Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts:possible implication of PPARγ[J]. Exp Dermatol,2013,22(1):41-47.
[13]	.LEE Y H,LEE N H,BHATTARAI G,et al.PPARgamma inhibits inflammatory reaction in oxidative stress induced human diploid fibloblast[J]. Cell Biochem Funct,2010,28(6):490-496.
[14]	.FERRONI P,DELLA-MORTE D,PILEGGI A,et al.Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus[J]. Curr Vasc Pharmacol,2013,11(3):338-351.
[15]	.DONG C,ZHOU H,SHEN C,et al.Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome[J]. World J Diabetes,2015,6(4):654-661.
[16]	.CARIOU B,CHARBONNEL B,STAELS B.Thiazolidinediones and PPARγ agonists:time for a reassessment[J]. Trends Endocrinol Metab,2012,23(5):205-215.
[17]	.MONTAGNER A,RANDO G,DEGUEURCE G,et al.New insights into the role of PPARs[J]. Prostaglandins Leukot Essent Fatty Acids,2011,85(5):235-243.
[18]	.CELINSKI K,DWORZANSKI T,FORNAL R,et al.Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis[J]. J Physiol Pharmacol,2012,63(6):631-640.
[19]	.BOCHNER B S.Novel therapies for eosinophilic disorders[J]. Immunol Allergy Clin North Am,2015,35(3):577-598.
[20]	.POL C J,LIEU M,DROSATOS K.PPARs:protectors or opponents of myocardial function?[J]. PPAR Res,2015,2015:835985.
[21]	.LIU J,WANG L N. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack[J]. Cochrane Database Syst Rev,2015,10:CD10693.
[22]	.LEE W S,KIM J.Peroxisome proliferator-activated receptors and the heart:lessons from the past and future directions[J]. PPAR Res,2015,2015:271983.
[23]	.CAMPOS A C,FOGACA M V,SONEGO A B,et al.Cannabidiol,neuroprotection and neuropsychiatric disorders[J]. Pharmacol Res,2016,112:119-127.
[24]	.QUINTANILLA R A,UTRERAS E,CABEZAS-OPAZO FA.Role of PPARγ in the differentiation and function of neurons[J]. PPAR Res,2014,2014:768594.
[25]	.BERGER J,MOLLER D E.The mechanisms of action of PPARs[J]. Annu Rev Med,2002,53:409-435.
[26]	.李颀,王岩,邱一凡,等. ALOX12基因多态性与糖尿病和糖尿病肾病的相关性研究[J]. 检验医学,2014,29(3):219-225.
[27]	.周贤会,郭开军. 胰岛素联合罗格列酮治疗2型糖尿病患者血清IL-6和脂联素水平的变化[J]. 检验医学,2008,23(1):14-17.
[28]	.REN P,ZHANG Y,HUANG Y,et al.Functions of peroxisome proliferator-activated receptor gamma (PPARγ) in gynecologic disorders[J]. Clin Med Insights Oncol,2015,9:43-49.
[29]	.MARTIN H.Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components[J]. Mutat Res,2009,669(1-2):1-7.
[30]	.LEHRKE M,LAZAR M A.The many faces of PPARgamma[J]. Cell,2005,123(6):993-999.
[31]	.BERNARDO A,MINGHETTI L.PPAR-gamma agonists as regulators of microglial activation and brain inflammation[J]. Curr Pharm Des,2006,12(1):93-109.